The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1654
ISSUE1654
July 11, 2022
Daridorexant (Quviviq) for Insomnia
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Daridorexant (Quviviq) for Insomnia
July 11, 2022 (Issue: 1654)
The FDA has approved daridorexant (Quviviq –
Idorsia), an orexin receptor antagonist, for treatment
of sleep-onset and/or sleep-maintenance insomnia
in adults. Daridorexant is the third orexin receptor
antagonist to be approved for this...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.